{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:55:00Z","timestamp":1789134900880,"version":"build-2803163510"},"reference-count":31,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Metastatic castration-resistant prostate cancer poses a therapeutic challenge with poor prognosis. The VISION trial showed prolonged progression-free and overall survival in patients treated with lutetium Lu 177 vipivotide tetraxetan (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617) radioligand therapy compared with using the standard of care (SoC) alone. The objective of this study was to determine the cost-effectiveness of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 treatment compared with SoC therapy.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A partitioned survival model was developed using data from the VISION trial, which included overall and progression-free survival and treatment regimens for\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 and SoC. Treatment costs, utilities for health states, and adverse events were derived from public databases and the literature. Because\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 was only recently approved, costs for treatment were extrapolated from\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE. Outcome measurements included the incremental cost, effectiveness, and cost-effectiveness ratio. The analysis was performed in a US setting from a healthcare system perspective over the lifetime horizon of 60 months. The willingness-to-pay threshold was set to $50,000, $100,000, and $200,000 per quality-adjusted life years (QALYs).\n                    <jats:bold>Results:<\/jats:bold>\n                    The\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 group was estimated to gain 0.42 incremental QALYs. Treatment using\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 led to an increase in costs compared with SoC ($169,110 vs $85,398). The incremental cost, effectiveness, and cost-effectiveness ratio for\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 therapy was $200,708\/QALYs. Sensitivity analysis showed robustness of the model regarding various parameters, which remained cost-effective at all lower and upper parameter bounds. In probabilistic sensitivity analysis using Monte Carlo simulation with 10,000 iterations, therapy using\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 was determined as the cost-effective strategy in 37.14% of all iterations at a willingness-to-pay threshold of $200,000\/QALYs.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Treatment using\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 was estimated to add a notable clinical benefit over SoC alone. Based on the model results, radioligand therapy represents a treatment strategy for patients with metastatic castration-resistant prostate cancer with cost-effectiveness in certain scenarios.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2022.7070","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:33:38Z","timestamp":1673436818000},"page":"43-50.e2","source":"Crossref","is-referenced-by-count":36,"title":["Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.6004","volume":"21","author":[{"given":"Dirk","family":"Mehrens","sequence":"first","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina K.M.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Beyer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias F.","family":"Froelich","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim-University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Tollens","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim-University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"R\u00fcbenthaler","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Herlemann","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler WP","year":"2017","unstructured":"Fendler WP, Reinhardt S, Ilhan H,  Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 2017;8:3581\u20133590.10.18632\/oncotarget.12240"},{"key":"B2","series-title":"J Nucl Med","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar K","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C,  German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017;58:85\u201390.10.2967\/jnumed.116.183194"},{"key":"B3","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor O","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN,  Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091\u20131103.10.1056\/NEJMoa2107322"},{"key":"B4","series-title":"Value Health","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau D","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F,  Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health 2022;25:10\u201331.10.1016\/j.jval.2021.10.008"},{"key":"B5","article-title":"CMS drug spending","unstructured":"Centers for Medicare & Medicaid Services. CMS drug spending. Accessed April 28, 2022. Available at: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Information-on-Prescription-Drugs"},{"key":"B6","article-title":"Overview of the Medicare physician fee schedule search","unstructured":"Centers for Medicare & Medicaid Services. Overview of the Medicare physician fee schedule search. Accessed April 28, 2022. Available at: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"B7","series-title":"Front Oncol","doi-asserted-by":"publisher","first-page":"627083","DOI":"10.3389\/fonc.2021.627083","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Sung WWY","year":"2021","unstructured":"Sung WWY, Choi HCW, Luk PHY,  A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Front Oncol 2021;11:627083.10.3389\/fonc.2021.627083"},{"key":"B8","series-title":"J Manag Care Spec Pharm","first-page":"1204","article-title":"Comparing clinical and economic outcomes associated with early initiation of combination therapy of an alpha blocker and dutasteride or finasteride in men with benign prostatic hyperplasia in the United States","volume":"22","author":"DerSarkissian M","year":"2016","unstructured":"DerSarkissian M, Xiao Y, Duh MS,  Comparing clinical and economic outcomes associated with early initiation of combination therapy of an alpha blocker and dutasteride or finasteride in men with benign prostatic hyperplasia in the United States. J Manag Care Spec Pharm 2016;22:1204\u20131214."},{"key":"B9","article-title":"Pharmaceutical prices","unstructured":"U.S. Department of Veterans Affairs, Office of Procurement, Acquisition, and Logistics. Pharmaceutical prices. Accessed September 1, 2022. Available at: https:\/\/www.va.gov\/opal\/nac\/fss\/pharmPrices.asp"},{"key":"B10","article-title":"Find drugs & conditions","unstructured":"Drugs.com. Find drugs & conditions. Accessed September 13, 2021. Available at: https:\/\/www.drugs.com"},{"key":"B11","article-title":"Initial economic guidance report: lutetium Lu 177 dotatate (lutathera) for gastroenteropancreatic neuroendocrine tumors","unstructured":"pan-Canadian Oncology Drug Review. Initial economic guidance report: lutetium Lu 177 dotatate (lutathera) for gastroenteropancreatic neuroendocrine tumors. Accessed September 1, 2022. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10142LutetiumLu177dotatateGEP-NET_inEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf"},{"key":"B12","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12885-020-07754-9","article-title":"Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance","volume":"21","author":"Zhang PF","year":"2021","unstructured":"Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. BMC Cancer 2021;21:35.10.1186\/s12885-020-07754-9"},{"key":"B13","series-title":"Palliat Med Rep","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/pmr.2020.0023","article-title":"Hospice or hospital: the costs of dying of cancer in the oncology care model","volume":"1","author":"Hoverman JR","year":"2020","unstructured":"Hoverman JR, Mann BB, Phu S,  Hospice or hospital: the costs of dying of cancer in the oncology care model. Palliat Med Rep 2020;1:92\u201396.10.1089\/pmr.2020.0023"},{"key":"B14","series-title":"Front Pharmacol","doi-asserted-by":"publisher","first-page":"610601","DOI":"10.3389\/fphar.2020.610601","article-title":"Cost-effectiveness of genomic test-directed olaparib for metastatic castration-resistant prostate cancer","volume":"11","author":"Su D","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of genomic test-directed olaparib for metastatic castration-resistant prostate cancer. Front Pharmacol 2021;11:610601.10.3389\/fphar.2020.610601"},{"key":"B15","series-title":"Med Decis Making","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0272989X07300604","article-title":"A review and meta-analysis of prostate cancer utilities","volume":"27","author":"Bremner KE","year":"2007","unstructured":"Bremner KE, Chong CA, Tomlinson G,  A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27:288\u2013298.10.1177\/0272989X07300604"},{"key":"B16","series-title":"J Med Econ","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1080\/13696998.2019.1661581","article-title":"Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance","volume":"22","author":"Barqawi YK","year":"2019","unstructured":"Barqawi YK, Borrego ME, Roberts MH,  Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. J Med Econ 2019;22:1202\u20131209.10.1080\/13696998.2019.1661581"},{"key":"B17","series-title":"Curr Oncol","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.3747\/co.23.2244","article-title":"Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada","volume":"23","author":"Amdahl J","year":"2016","unstructured":"Amdahl J, Diaz J, Park J,  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol 2016;23:e340\u2013354.10.3747\/co.23.2244"},{"key":"B18","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.05.2067","article-title":"Health state utilities among metastatic castrate-resistant prostate cancer patients with and without symptomatic skeletal events [abstract]","volume":"90","author":"Donga P","year":"2014","unstructured":"Donga P, Bilir P, Valderrama A,  Health state utilities among metastatic castrate-resistant prostate cancer patients with and without symptomatic skeletal events [abstract]. Int J Radiat Oncol Biol Phys 2014;90(Suppl 1):Abstract 3259.10.1016\/j.ijrobp.2014.05.2067"},{"key":"B19","series-title":"FEBS Lett","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/0014-5793(69)80071-2","article-title":"Computer simulation of stochastic processes through model-sampling (Monte Carlo) techniques","volume":"2","author":"Sheppard CW","year":"1969","unstructured":"Sheppard CW. Computer simulation of stochastic processes through model-sampling (Monte Carlo) techniques. FEBS Lett 1969;2(Suppl 1):S14\u201321.10.1016\/0014-5793(69)80071-2"},{"key":"B20","series-title":"Asian J Urol","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer","volume":"4","author":"Pollard ME","year":"2017","unstructured":"Pollard ME, Moskowitz AJ, Diefenbach MA,  Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian J Urol 2017;4:37\u201343.10.1016\/j.ajur.2016.11.005"},{"key":"B21","series-title":"BJU Int","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)","volume":"124","author":"Hofman MS","year":"2019","unstructured":"Hofman MS, Emmett L, Violet J,  TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int 2019;124(Suppl 1):5\u201313.10.1111\/bju.14876"},{"key":"B22","series-title":"Curr Oncol","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3747\/co.26.4395","article-title":"The economic impact of the transition from branded to generic oncology drugs","volume":"26","author":"Cheung WY","year":"2019","unstructured":"Cheung WY, Kornelsen EA, Mittmann N,  The economic impact of the transition from branded to generic oncology drugs. Curr Oncol 2019;26:89\u201393.10.3747\/co.26.4395"},{"key":"B23","series-title":"Expert Rev Anticancer Ther","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/14737140.2014.856270","article-title":"Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer","volume":"14","author":"Holko P","year":"2014","unstructured":"Holko P, Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014;14:63\u201373.10.1586\/14737140.2014.856270"},{"key":"B24","series-title":"Eur J Nucl Med Mol Imaging","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00259-020-05102-4","article-title":"177Lu-PSMA for advanced prostate cancer: are we ready to play big?","volume":"48","author":"Hehakaya C","year":"2021","unstructured":"Hehakaya C, Moors EHM, Verkooijen HM,  177Lu-PSMA for advanced prostate cancer: are we ready to play big? Eur J Nucl Med Mol Imaging 2021;48:2325\u20132328.10.1007\/s00259-020-05102-4"},{"key":"B25","series-title":"J Med Econ","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1080\/13696998.2020.1830286","article-title":"Cost-effectiveness of lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France","volume":"23","author":"Leeuwenkamp OR","year":"2020","unstructured":"Leeuwenkamp OR, Smith-Palmer J, Ortiz R,  Cost-effectiveness of lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. J Med Econ 2020;23:1534\u20131541.10.1080\/13696998.2020.1830286"},{"key":"B26","series-title":"World J Clin Cases","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.12998\/wjcc.v8.i20.4793","article-title":"Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden","volume":"8","author":"Palmer J","year":"2020","unstructured":"Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020;8:4793\u20134806.10.12998\/wjcc.v8.i20.4793"},{"key":"B27","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12885-021-08306-5","article-title":"Initiation of somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis","volume":"21","author":"Rustgi SD","year":"2021","unstructured":"Rustgi SD, Oh A, Yang JY,  Initiation of somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597.10.1186\/s12885-021-08306-5"},{"key":"B28","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12885-020-07710-7","article-title":"Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland","volume":"21","author":"Smith-Palmer J","year":"2021","unstructured":"Smith-Palmer J, Leeuwenkamp OR, Virk J,  Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 2021;21:10.10.1186\/s12885-020-07710-7"},{"key":"B29","series-title":"Eur Urol","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"de Feria Cardet RE","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T,  Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol 2021;79:413\u2013418.10.1016\/j.eururo.2020.11.043"},{"key":"B30","series-title":"J Nucl Med","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach PJ","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L,  The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med 2018;59:82\u201388.10.2967\/jnumed.117.197160"},{"key":"B31","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler WP","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A,  Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019;25:7448\u20137454.10.1158\/1078-0432.CCR-19-1050"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/1\/article-p43.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/1\/article-p43.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/1\/article-p43.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:34:02Z","timestamp":1673436842000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/1\/article-p43.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7070","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}